Tavo Biotherapeutics Appoints Federico Grossi As Chief Medical Officer

Company

Location

About

Tavo Biotherapeutics is developing innovative treatments to address critical unmet needs in ophthalmology. TAV-001 engages two novel targets that represent fundamental mechanisms underlying the pathology of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown signals of neuroprotection as well as substantial reduction in intraocular pressure, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic retinopathy, diabetic macular edema, and both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program.